Post by
jolew32 on Jan 13, 2023 8:55am
Biogen looking to get new Alzheimer's drug Lecanemab approve
Eisai & Biogen applied on Jan 10, 2023 to get Lecanemab approved in Europe. They got fast track approval in the U.S. on Jan 6, 2023 and applied to China for approval on Dec 22, 2022.
E&B are pursuing the 3 biggest markets in the world for their new Alzheimer's drug Lecanemab.
A dementia doctor in Toronto described Lecanemab as a game changing drug that can add years of additional independence for early Alzheimer's patients.
CognICA is the only digital test today capable of detecting early Alzheimer's efficiently, effectively, and across whole populations because of its very low cost compared to alternative testing methods such as blood tests and brain scans.
CognICA is currently approved in the U.S. and Europe, but not in China.
CGN needs to get CognICA approved in China as well asap so that it's available for early Alzheimer's testing when E&B's new Alzheimer's drug Lecanemab gets approved.